Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population
GlaxoSmithKline Korea has submitted a registration file for its hepatitis A vaccine. The present study will collect clinical data in the local target population as per the requirement of Korean Food and Drugs administration (FDA).
|Study Design:||Time Perspective: Prospective|
|Official Title:||A Multicentric, Post-Marketing Surveillance to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals Hepatitis A Vaccine Administered in Korean Population.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00237991
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|